English
Back
Download
Log in to access Online Inquiry
Back to the Top

Only took a day! Hehehe

$Vaccinex (VCNX.US)$ Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab
in Alzheimer’s Disease
Results affirm expectation of a novel mechanism of action targeting astrocyte activation to
delay progression of Alzheimer’s disease from early stage Mild Cognitive Impairment
Findings echo previous phase 2 results in Huntington’s disease based on similarities to
neuroimmune pathology in Alzheimer’s
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
1
Translate
Report
2530 Views
Comment
Sign in to post a comment
3065Followers
29Following
45KVisitors
Follow